(Q48586166)

English

Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

author name string

G Hildebrandt

1

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

J Zierski

2

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

G Csecsei

3

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

H W Mueller

4

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

H Stracke

5

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

publication date

1 January 1992

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

Acta Neurochirurgica

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

117

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

3-4

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

160-165

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circadian variation of basal plasma growth hormone in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased growth hormone pulse frequency in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PET as a tool in the clinical evaluation of pituitary adenomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical review 22: Therapeutic options in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of the mu-opiate receptor in peripheral analgesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1414517

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01400614

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 February 2018

http://europepmc.org/abstract/MED/1414517

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48586166&oldid=2209614722"